|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADD1 |
Gene summary for ADD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADD1 | Gene ID | 118 |
| Gene name | adducin 1 | |
| Gene Alias | ADDA | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0001885 | UniProtAcc | P35611 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 118 | ADD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.71e-09 | 5.86e-01 | -0.1954 |
| 118 | ADD1 | F007 | Human | Colorectum | FAP | 4.15e-02 | -2.05e-01 | 0.1176 |
| 118 | ADD1 | A002-C-010 | Human | Colorectum | FAP | 4.68e-03 | -2.74e-01 | 0.242 |
| 118 | ADD1 | A001-C-207 | Human | Colorectum | FAP | 8.23e-06 | -2.35e-01 | 0.1278 |
| 118 | ADD1 | A015-C-203 | Human | Colorectum | FAP | 2.34e-25 | -2.89e-01 | -0.1294 |
| 118 | ADD1 | A015-C-204 | Human | Colorectum | FAP | 3.04e-07 | -2.69e-01 | -0.0228 |
| 118 | ADD1 | A014-C-040 | Human | Colorectum | FAP | 3.71e-05 | -3.68e-01 | -0.1184 |
| 118 | ADD1 | A002-C-201 | Human | Colorectum | FAP | 2.71e-16 | -3.11e-01 | 0.0324 |
| 118 | ADD1 | A001-C-119 | Human | Colorectum | FAP | 2.81e-05 | -2.00e-01 | -0.1557 |
| 118 | ADD1 | A001-C-108 | Human | Colorectum | FAP | 2.43e-10 | -1.66e-01 | -0.0272 |
| 118 | ADD1 | A002-C-205 | Human | Colorectum | FAP | 6.83e-23 | -3.47e-01 | -0.1236 |
| 118 | ADD1 | A015-C-005 | Human | Colorectum | FAP | 9.15e-05 | -2.01e-01 | -0.0336 |
| 118 | ADD1 | A015-C-006 | Human | Colorectum | FAP | 6.32e-16 | -3.41e-01 | -0.0994 |
| 118 | ADD1 | A015-C-106 | Human | Colorectum | FAP | 1.65e-10 | -2.09e-01 | -0.0511 |
| 118 | ADD1 | A002-C-114 | Human | Colorectum | FAP | 3.36e-20 | -2.94e-01 | -0.1561 |
| 118 | ADD1 | A015-C-104 | Human | Colorectum | FAP | 3.16e-23 | -2.97e-01 | -0.1899 |
| 118 | ADD1 | A001-C-014 | Human | Colorectum | FAP | 4.14e-11 | -2.12e-01 | 0.0135 |
| 118 | ADD1 | A002-C-016 | Human | Colorectum | FAP | 3.77e-18 | -2.55e-01 | 0.0521 |
| 118 | ADD1 | A015-C-002 | Human | Colorectum | FAP | 2.69e-15 | -5.14e-01 | -0.0763 |
| 118 | ADD1 | A001-C-203 | Human | Colorectum | FAP | 2.89e-09 | -1.27e-01 | -0.0481 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003083216 | Oral cavity | OSCC | regulation of actin filament length | 104/7305 | 189/18723 | 5.48e-06 | 6.14e-05 | 104 |
| GO:003083318 | Oral cavity | OSCC | regulation of actin filament polymerization | 96/7305 | 172/18723 | 5.56e-06 | 6.20e-05 | 96 |
| GO:000815418 | Oral cavity | OSCC | actin polymerization or depolymerization | 117/7305 | 218/18723 | 7.38e-06 | 8.04e-05 | 117 |
| GO:003004118 | Oral cavity | OSCC | actin filament polymerization | 103/7305 | 191/18723 | 1.94e-05 | 1.87e-04 | 103 |
| GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
| GO:003133318 | Oral cavity | OSCC | negative regulation of protein-containing complex assembly | 79/7305 | 141/18723 | 3.01e-05 | 2.76e-04 | 79 |
| GO:005101720 | Oral cavity | OSCC | actin filament bundle assembly | 86/7305 | 157/18723 | 4.28e-05 | 3.70e-04 | 86 |
| GO:006157220 | Oral cavity | OSCC | actin filament bundle organization | 87/7305 | 161/18723 | 7.49e-05 | 5.84e-04 | 87 |
| GO:00018859 | Oral cavity | OSCC | endothelial cell development | 40/7305 | 64/18723 | 1.20e-04 | 8.57e-04 | 40 |
| GO:006102816 | Oral cavity | OSCC | establishment of endothelial barrier | 30/7305 | 46/18723 | 2.86e-04 | 1.80e-03 | 30 |
| GO:00432445 | Oral cavity | OSCC | regulation of protein-containing complex disassembly | 65/7305 | 121/18723 | 7.08e-04 | 3.90e-03 | 65 |
| GO:000315816 | Oral cavity | OSCC | endothelium development | 71/7305 | 136/18723 | 1.18e-03 | 5.99e-03 | 71 |
| GO:007124115 | Oral cavity | OSCC | cellular response to inorganic substance | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00454469 | Oral cavity | OSCC | endothelial cell differentiation | 61/7305 | 118/18723 | 3.40e-03 | 1.44e-02 | 61 |
| GO:004521618 | Oral cavity | OSCC | cell-cell junction organization | 97/7305 | 200/18723 | 3.83e-03 | 1.57e-02 | 97 |
| GO:00436244 | Oral cavity | OSCC | cellular protein complex disassembly | 68/7305 | 136/18723 | 5.84e-03 | 2.24e-02 | 68 |
| GO:190290417 | Oral cavity | OSCC | negative regulation of supramolecular fiber organization | 81/7305 | 167/18723 | 7.70e-03 | 2.82e-02 | 81 |
| GO:007124816 | Oral cavity | OSCC | cellular response to metal ion | 93/7305 | 197/18723 | 1.14e-02 | 3.85e-02 | 93 |
| GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
| GO:190290326 | Oral cavity | EOLP | regulation of supramolecular fiber organization | 93/2218 | 383/18723 | 6.50e-12 | 1.08e-09 | 93 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADD1 | SNV | Missense_Mutation | c.1276N>A | p.Asp426Asn | p.D426N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.452) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| ADD1 | SNV | Missense_Mutation | rs370911124 | c.76N>A | p.Asp26Asn | p.D26N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.1901N>C | p.Asp634Ala | p.D634A | P35611 | protein_coding | tolerated(0.2) | benign(0.075) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
| ADD1 | SNV | Missense_Mutation | rs760404515 | c.1924N>T | p.Pro642Ser | p.P642S | P35611 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.2224N>T | p.Pro742Ser | p.P742S | P35611 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ADD1 | insertion | In_Frame_Ins | novel | c.1902_1903insAGGGAGGAGGAATCTAGAGAGGCAGTCTGGCTA | p.Asp634_Gln635insArgGluGluGluSerArgGluAlaValTrpLeu | p.D634_Q635insREEESREAVWL | P35611 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ADD1 | insertion | Nonsense_Mutation | novel | c.1925_1926insTTAAACTTCTGAAATAAAGACAGAGA | p.Pro643Ter | p.P643* | P35611 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| ADD1 | deletion | Frame_Shift_Del | novel | c.533delN | p.Glu178AspfsTer15 | p.E178Dfs*15 | P35611 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ADD1 | SNV | Missense_Mutation | novel | c.1145G>A | p.Arg382Gln | p.R382Q | P35611 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ADD1 | SNV | Missense_Mutation | c.85N>C | p.Asp29His | p.D29H | P35611 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 118 | ADD1 | KINASE | bumetanide | BUMETANIDE | 20877298 | |
| 118 | ADD1 | KINASE | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 19057513,14553962,18591455,11882573,9149697,12623934,10523341 | |
| 118 | ADD1 | KINASE | furosemide | FUROSEMIDE | 20877298,21692745 | |
| 118 | ADD1 | KINASE | torasemide | TORSEMIDE | 20877298 | |
| 118 | ADD1 | KINASE | spironolactone | SPIRONOLACTONE | 21692745 | |
| 118 | ADD1 | KINASE | diuretics | 17189961,11926892 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |